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Summary
Age-related macular degeneration (AMD) is the most
common geriatric eye disorder leading to blindness and
is characterized by degeneration of the neuroepithelium
in the macular area of the eye. Apolipoprotein E (apoE),
the major apolipoprotein of the CNS and an important
regulator of cholesterol and lipid transport, appears to
be associated with neurodegeneration. The apoE gene
(APOE) polymorphism is a strong risk factor for various
neurodegenerative diseases, and the apoE protein has
been demonstrated in disease-associated lesions of these
disorders. Hypothesizing that variants of APOE act as
a potential risk factor for AMD, we performed a genetic-
association study among 88 AMD cases and 901 con-
trols derived from the population-based Rotterdam
Study in the Netherlands. The APOE polymorphism
showed a significant association with the risk for AMD;
the APOE e4 allele was associated with a decreased risk
(odds ratio 0.43 [95% confidence interval 0.21–0.88]),
and the e2 allele was associated with a slightly increased
risk of AMD (odds ratio 1.5 [95% confidence interval
0.8–2.82]). To investigate whether apoE is directly in-
volved in the pathogenesis of AMD, we studied apoE
immunoreactivity in 15 AMD and 10 control maculae
and found that apoE staining was consistently present
in the disease-associated deposits in AMD-maculae–that
is, drusen and basal laminar deposit. Our results suggest
that APOE is a susceptibility gene for AMD.
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Introduction
Age-related macular degeneration (AMD) is the most
common cause of blindness in the elderly in developed
countries (Sommer et al. 1991; Klein et al. 1995; Attebo
et al. 1996; Klaver et al. 1998), severely affecting 110%
of octo- and nonagenarians (Vingerling et al. 1995). His-
topathologically, the hallmark of early AMD is accu-
mulation of extracellular drusen and basal laminar de-
posit (van der Schaft et al. 1992; Green and Enger 1993;
Kliffen et al. 1997); the end stage is characterized by a
complete degeneration of the neurosensory retina and
of the underlying retinal pigment epithelium in the mac-
ular area (Sarks 1976). The etiology of AMD is largely
unknown, but the current understanding is that AMD
is a genetically complex eye disorder (Heiba et al. 1994;
Klaver et al. 1997; Seddon et al. 1997) possibly caused
by a variety of molecular defects. Less frequent macular
disorders have been linked to a significant number of
genomic loci (Small et al. 1992, 1996; Stone et al. 1992,
1994; Evans et al. 1994; Gregory et al. 1996), whereas
mutations in the TIMP3 (Weber et al. 1994) and peri-
pherin/RDS (Nichols et al. 1993; Weleber et al. 1993;
Wells et al. 1993; Keen et al. 1994; Nakazawa et al.
1994; Hoyng et al. 1996) genes have been identified in
specific earlier-onset retinal dystrophies. Despite close
clinical similarities between AMD and these disorders,
neither the TIMP3 gene nor the peripherin/RDS gene
has been associated with AMD. A recent publication
reports that the Stargardt disease gene shows a consistent
variation of the ABCR gene in 4.2% of AMD patients,
significantly different from the 0.45% in population con-
trols (Allikmets et al. 1997). This variation may account
for ∼4% of the total occurrence of AMD, and, presum-
ably, more genes are involved.
Apolipoprotein E (apoE) is unique among apolipo-
proteins, in its special relevance to nervous tissue. It mo-
bilizes and redistributes lipids, in maintenance and repair
of neuronal cell membranes (Pitas et al. 1987; Mahley
1988; Boyles et al. 1989), thereby playing a pivotal role
in the reinnervation process following peripheral nerv-
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Table 1
Distribution of APOE Genotypes and Allele Frequency
APOE CHARACTERISTIC
FREQUENCY IN
AMD Cases
(n 5 88)
Controls
(n 5 901)
Genotype:
E2E2 .000 .010
E2E3 .227 .144
E2E4 .023 .017
E3E3 .636 .555
E3E4 .114a .252
E4E4 .000 .022
Allele frequency:
e2 .125 .090
e3 .806 .753
e4 .068b .156
a P 5 .02, compared with controls.
b P 5 .004, compared with controls. Hardy-Weinberg equilibrium:
cases x2 5 2.27, P 5 .26; controls x2 5 4.24, P 5 .11.
ous system (Ignatius et al. 1986) and CNS injury (Poirier
et al. 1993). The gene for apoE (APOE), located on
chromosome 19q13.2 (Olaisen et al. 1982), is poly-
morphic, with the occurrence of three common alleles:
e2, e3, and e4. The e3 allele is considered to be the
ancestral allele; and e2 and e4 are considered as variants,
on the basis of single point mutations (Mahley 1988).
APOE’s polymorphism is of particular interest within
the framework of neurodegeneration, for it is strongly
associated with the risk of Alzheimer disease (Stritt-
matter et al. 1993; Farrer et al. 1997) and may be as-
sociated with various other neurodegenerative disorders
(Amouyel et al. 1994; Al-Chalabi et al. 1996). Moreover,
apoE is expressed in lesions that characterize Alzheimer
disease, Down syndrome, and prion diseases (Namba et
al. 1991; Wisniewski and Frangione 1992).
Expanding these data to a neurodegenerative eye dis-
order, we investigated the possible role of APOE in AMD
in a genetic-association study. We have used a case-con-
trol design implemented within a population-based
study, to assess whether the APOE alleles are associated
with the risk of AMD. In a subsequent immunohisto-
chemical procedure, we studied apoE expression in hu-
man maculae with and without AMD.
Subjects and Methods
We studied APOE genotype and allele frequencies in
AMD cases and in controls in the Rotterdam Study, a
population-based study, in the Netherlands, of subjects
age x55 years. The rationale and design of the Rotter-
dam Study have been described elsewhere (Hofman et
al. 1991; Vingerling et al. 1995). A total of 6,775 par-
ticipants in that study had undergone an extensive oph-
thalmological examination, including fundus photog-
raphy. Diagnosis of AMD was based on grading of
fundus transparencies according to an internationally
accepted classification system (Bird et al. 1995). Cases
were all subjects with end stages of AMD on whom data
on APOE genotype were available (n 5 88). The end
stages comprised atrophic macular degeneration—that
is, geographic areas of atrophy of the retinal pigment
epithelium and choriocapillaris—and neovascular mac-
ular degeneration—that is, serous or hemorrhagic de-
tachment of the pigment epithelium or choroidal neo-
vascularization. Controls were a randomly selected
sample of study subjects without atrophic or neovascular
AMD (n 5 901). There were no significant differences,
in baseline characteristics, between cases and controls,
apart from the known risk factors age and atheroscle-
rosis (mean age [SD] 81 [8] vs. 69 [9] years, P ! .001;
frequency of lower-extremity arterial disease [an indi-
cator of atherosclerosis] 37% vs. 16%, P ! .001 [age-
adjusted prevalence data]).
Genomic DNA was extracted from peripheral blood
leukocytes, and the subsequent analysis of APOE geno-
types was performed as described elsewhere (Wenham
et al. 1991; van Duijn et al. 1994). Genotype and allele
distributions between cases and controls were calculated
by use of x2 statistics. With multiple logistic-regression
analysis, we estimated the odds ratio (OR), as a measure
of relative risk, for the various genotypes, using the an-
cestral E3E3 genotype as a reference. ORs were adjusted
for age and gender and, in a separate analysis, for the
presence of lower-extremity arterial disease, to investi-
gate the possible confounding effect of atherosclerosis.
For the immunohistochemical study, maculae were
obtained from 25 human eye-bank eyes from 25 sub-
jects. The times from death to processing of the maculae
were 1–10 h, with a mean of 7 h. Tissues were fixed in
4% formaldehyde, embedded in paraffin, and sectioned
into 5-mm thicknesses. Sections were stained with he-
matoxylin-eosin, the periodic-acid–Schiff reaction, and
Mallory staining and subsequently were classified his-
tologically according to quantification of drusen and
basal laminar deposit, as described elsewhere (van der
Schaft et al. 1992; Kliffen et al. 1997). Accordingly, mac-
ulae with no or only solitary patches of basal laminar
deposit and with no more than three drusen were clas-
sified as controls (n 5 10); and maculae with a contin-
uous layer of basal laminar deposit and/or with many
or confluent drusen were classified as cases (n 5 15).
Cases were, although not significantly, older than con-
trols (mean age [SD] 82 [10] vs. 72 [14] years; P 5 .08).
After deparaffinization and rehydration, sections were
incubated with 5.5 mU/ml pronase E (Sigma), to reveal
antigenic epitopes of APOE, and were placed in a Se-
quenza Immunostaining Workstation (Life Sciences In-
ternational). Sections were successively incubated with
a mouse-monoclonal antibody directed against apoE
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Figure 1 APOE allele frequencies in the age categories of 55–75
years, 75–85 years, and 185 years: the number of cases and the number
of controls, respectively, in these successive categories are 17 and 687,
40 and 188, and 26 and 31.
Table 2
Relative Risk of AMD for the APOE Genotypes
APOE GENOTYPEa
NO. OF
OR (95% CONFIDENCE
INTERVAL)
AMD Cases
(n 5 88)
Controls
(n 5 901) Crude Adjustedb
E*2 22 154 1.28 (.75–2.21) 1.50 (.80–2.82)
E3E3 56 500 Reference Reference
E*4 12 262 .41 (.22–.78) .43 (.21–.88)
a APOE genotypes with the e2 allele are grouped, and genotypes with the e4 allele
are grouped; subjects with the E2E4 genotype (2 of 88 cases, 15 of 901 controls) are
present in both the E*2 group and the E*4 group.
b For age and gender.
(clone 3D12, dilution 1:25; Monosan), biotinylated-sec-
ondary antibodies (Multilink, dilution 1:75; Biogenex),
and alkaline-phosphatase–conjugated streptavidin (di-
lution 1:50; Biogenex). Between these incubations, sec-
tions were washed thoroughly with PBS. After a final
rinsing with 0.2 M Tris-HCl pH 8.0, the presence of
apoE was visualized with 0.3% New Fuchsin/Tris-HCl
(Sigma).
Results
APOE genotype and allele distributions differed sig-
nificantly between cases and controls (table 1). Com-
pared with controls, the frequency of the APOE e4 allele
was significantly lower among cases (.07 in cases vs. 0.16
in controls; P 5 .002), whereas the frequency of the e2
allele was, although not significantly, higher (.13 vs. .09;
P 5 .17 ). Because the e4 allele may adversely affect
longevity, given its association with Alzheimer disease
and coronary heart disease (Kervinen et al. 1993), we
investigated the prevalence of the APOE alleles, as a
function of age (fig. 1). There were no significant dif-
ferences in allele frequencies in the three age groups,
indicating that our findings cannot be explained by the
age-distribution difference between cases and controls.
Table 2 shows the relative risks of AMD, for the dif-
ferent APOE alleles. When adjustment was made for age
and sex, subjects with the e4 allele were more than two
times less likely to develop AMD than were subjects with
the E3E3 genotype. Subjects with the e2 allele were at
a slightly, but not significantly, increased risk of AMD.
Additional adjustment, for lower-extremity arterial dis-
ease, did not significantly alter the risk estimates (data
not shown), suggesting that APOE and atherosclerosis
are independent risk factors for AMD.
apoE immunoreactivity was present in the extracel-
lular deposits that characterized the AMD macu-
lae—that is, basal laminar deposit and soft drusen. Basal
laminar deposit stained positive for apoE in 13 of 15
maculae with this type of deposit (fig. 2A), and drusen
stained positive in 9 of 11 maculae with drusen (fig. 2B).
One eye with atrophic AMD showed both a thick layer
of basal laminar deposit and drusen staining positive for
apoE (fig. 2C). In both case and control maculae, stain-
ing was seen in the outer collagenous zone of Bruch’s
membrane, in blood vessels, and in Mu¨ller cells. Partic-
ularly of interest is the finding that solitary, hard hyaline
drusen, a type of deposit that is clinically not associated
with AMD, did not show any apoE immunoreactivity.
Discussion
Our results show that the APOE polymorphism is sig-
nificantly associated with the risk of AMD and that apoE
is expressed in lesions that characterize AMD. A de-
creased risk of AMD was associated with the e4 allele,
whereas an increased risk was associated with the e2
allele. The consistent immunoreactivity in soft drusen
and basal laminar deposit in the AMD maculae suggests
the importance of apoE in the pathogenesis of AMD.
Figure 2 Immunohistochemistry of apoE in human maculae with AMD. Shown is positive staining (red), of (A) a thin layer of basal
laminar deposit located between the retinal pigment epithelium (rpe) and Bruch’s membrane (arrow), (B) soft drusen (arrows), and (C) thick
layer of diffuse drusen in a subject with atrophic AMD (note disappearance of the photoreceptors and of most of the rpe). ONL 5 outer
nuclear layer; and PH 5 photoreceptors. (New Fuchsin; #400)
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We carefully avoided selection bias, a frequently en-
countered problem in association studies. Since cases
and controls were both derived from the same homo-
geneous source population, and since the distribution of
the APOE genotypes in cases and controls was in Hardy-
Weinberg equilibrium, selection on the basis of genotype
is unlikely. Moreover, the allele frequencies among the
controls were in close agreement with the average allele
frequencies estimated for the Dutch (Smit et al. 1988)
and other Caucasian populations (Davignon et al. 1988).
Because our extensive ophthalmologic examination de-
manded attentiveness from the study subjects, it may
have selected against other neurodegenerative dis-
eases—such as Alzheimer disease—which are known to
be associated with increased e4 frequency. Nevertheless,
this cannot account for allele-frequency differences be-
tween cases and controls, because both groups under-
went identical procedures. Finally, we showed that allele
frequencies were similar across all age groups (fig. 1),
indicating that the association cannot be explained on
the basis of age.
Given the limited amount of data available, we can
only speculate on the possible role of apoE in the neu-
ronal dynamics of the macular area. In the CNS in gen-
eral, a major physiological role for apoE is to mediate
the interaction between apoE-containing lipoproteins
and lipoprotein receptors, including the LDL receptor
(Goldstein et al. 1983) and the LDL receptor–related
protein receptor (LRP) (Kowal et al. 1989). After neu-
ronal cell loss, large amounts of lipids are released from
degenerating cell membranes and myelin, and, in re-
sponse, astrocytes synthesize apoE, to bind the free cho-
lesterol and lipids and to distribute them for reuse in
cell-membrane biosynthesis (Poirier et al. 1993, 1995).
ApoE may have a significant role in retinal membrane
renewal. The high turnover of photoreceptor membranes
(Grindle and Marshall 1978), especially in the macular
area, makes cell-membrane remodeling of critical im-
portance for maintaining the normal physiology of the
retina. Failure of this process may then result in macular
degeneration.
In the CNS, apoE is primarily synthesized by the major
glial cell, the astrocyte. In our series, cell bodies of the
Mu¨ller cell, the retinal analogue of the astrocyte, showed
significant apoE expression, which may indicate a site
of apoE production. This assumption is supported by
findings from previous reports, which show that these
cells are capable of apoE synthesis (Amaratunga et al.
1996) and which show increased expression in eyes with
retinal damage (Kuhrt et al. 1997). The distribution of
the LDL or LRP receptor in the neuroepithelium of the
eye is unknown, and it is therefore unclear which cells
are able to take up and process apoE-complexed mol-
ecules in this compartment. The retinal pigment-epithe-
lium cell, which has digestion of photoreceptor outer
segments as its primary function, may be an appropriate
candidate.
Interestingly, we found a reduced AMD risk for sub-
jects carrying the e4 allele, whereas for most other neu-
rodegenerative disorders the risk is increased for these
subjects. Isoform-specific alterations in apoE-lipoprotein
metabolism consist of differences in net charge (Davig-
non et al. 1988) and in total serum level (Utermann
1985) and brain level (Bertrand et al. 1995) of apoE.
Recently, it has been shown that the isoforms also differ
in cell-specific binding properties (Guillaume et al.
1996). apoE-mediated binding, internalization, and deg-
radation of lipids in the CNS appear to be different for
each apoE isoform, depending on the type of target cell.
A possible interpretation of our findings is that apoE
isoforms in the macular area may either differ in binding
affinity or elicit a response different than that at other
sites in the nervous system. Since it is not immediately
clear how the APOE alleles may be a source of genetic
risk for AMD, it will be intriguing to investigate whether
accumulation of deposits in AMD occurs in an isoform-
dependent manner.
An alternative explanation for our findings is that the
e4 allele is associated with a distinct mutation in a gene
in linkage disequilibrium with APOE. This may be the
gene that actually determines susceptibility to AMD. Ac-
cording to the August 1997 OMIM (Online Mendelian
Inheritance in Man), 20–30 genes are located in the im-
mediate vicinity of APOE, and they may be considered
in this context; among these genes, we could not find
an obvious candidate gene for retinal disease.
To conclude, we have shown a significant association
between APOE and AMD in a general population of
elderly people, and we have immunohistochemically lo-
calized apoE in defining lesions of AMD. Although in
need of confirmation, our data further emphasize the
role of APOE in neurodegeneration and may indicate
that we have identified a susceptibility gene for AMD.
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